Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
about
An integrated inspection of the somatic mutations in a lung squamous cell carcinoma using next-generation sequencingFirst- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.Pemetrexed plus cisplatin/carboplatin in previously treated locally advanced or metastatic non-small cell lung cancer patients.Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis.A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysisPemetrexed for the treatment of non-small-cell lung cancer.Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer.Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response AssessmentPemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature.Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Monoclonal antibodies in lung cancer.Pemetrexed for the treatment of non-small cell lung cancer.MiR-186 Inhibited Migration of NSCLC via Targeting cdc42 and Effecting EMT Process.
P2860
Q28390823-C7C7472F-D09E-427F-9B02-32D62867F6ABQ33373493-03461FFA-DD1E-456D-ACE7-7EA3EF5179A0Q33389316-C109755B-AE51-4778-9F66-FC422189570CQ33399254-4B9F18F4-EFA2-4D55-82DA-BF88B03DCE08Q33406103-3DF46F13-95C4-4892-95CA-AF95586F0418Q33424852-4D110D51-5767-4EC7-BD71-A402EBC7C0AEQ35003631-7EC3E975-6DCE-4D24-807E-C8C0CC367B39Q35146932-9F1CE239-A9B8-476A-9AE0-6CA29CE97002Q35583723-A0DDFA43-D0B4-4A05-9F1E-542442A49B04Q35784966-67FC7FD3-DDDE-40CB-89D2-4585858AA2B8Q37818301-91E0C305-4742-4996-A072-9C68E85F7366Q37945643-CCB9EF68-3C8C-41A0-A8D9-432F13C53817Q38067454-2C47D1B4-F1B7-4E08-90CB-F19CB9750735Q38107552-136E4EAC-EDF4-4FA6-9982-565633680D74Q38711597-5A9E92F2-F3BC-464F-A8B7-C0E1944D227A
P2860
Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical evidence for second- ...... ed non-small cell lung cancer.
@en
Clinical evidence for second- ...... ed non-small cell lung cancer.
@nl
type
label
Clinical evidence for second- ...... ed non-small cell lung cancer.
@en
Clinical evidence for second- ...... ed non-small cell lung cancer.
@nl
prefLabel
Clinical evidence for second- ...... ed non-small cell lung cancer.
@en
Clinical evidence for second- ...... ed non-small cell lung cancer.
@nl
P1433
P1476
Clinical evidence for second- ...... ced non-small cell lung cancer
@en
P2093
Filippo de Marinis
P356
10.1634/THEONCOLOGIST.13-S1-14
P478
13 Suppl 1
P577
2008-01-01T00:00:00Z